Please assess the completion status of the following clinical trial:

Trial Title: Effect of Losartan on Airway Mucociliary Dysfunction in Patients With COPD and Chronic Bronchitis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Fulfill one of the group definitions above~2. Age between 35 and 75 years old~3. Clinical diagnosis of chronic bronchitis, defined as productive cough for at least 3 months per year for at least two consecutive years~4. Stable maintenance of all current medication therapy for 3 months, including ARBs for treated groups~Exclusion criteria~1. Current therapy with Angiotensin-converting-enzyme (ACE) inhibitor,or Intolerance to Angiotensin II receptor blockers (ARB)~2. Women of child bearing potential~3. Current use of nonsteroidal antiinflammatory drugs or potassium supplementation, treatment with aliskiren, anticoagulation~4. COPD exacerbation requiring treatment within 6 weeks of the screening visit~5. Oral corticosteroid use within 6 weeks of the screening visit~6. Significant hypoxemia (oxygen saturation \<90% on room air), chronic respiratory failure by history (pCO2 \> 45 mmHg) and forced expiratory volume in 1 second (FEV1) below 40%, clinical evidence of cor pulmonale~7. Untreated arterial hypertension (systolic blood pressure \>140 mm Hg, diastolic blood pressure \> 90 mm Hg)~8. Ability to understand and willingness to sign consent documents~9. Blood pressure less than 100 mm Hg systolic or 70 mm Hg diastolic while standing at the screening visit~10. Cardiac, renal, hepatic (LFTs \> 3x normal upper limit), neurological, psychiatric, endocrine or neoplastic diseases that are at the discretion of the investigator, to interfere with participation in study~11. History of renal artery stenosis~12. Concomitant airway disorders other than COPD and chronic bronchitis, such as bronchiectasis and asthma (history and reversible airflow obstruction by American Thoracic Society (ATS) criteria)~13. History of pulmonary malignancies, and any other malignancies in the last 5 years~14. History of thoracic surgery.~15. Acute pulmonary exacerbation within 6 weeks from the Screening Visit.~16. Subjects with no airflow obstruction by spirometry but with a decrease in diffusing capacity of lung for carbon monoxide(DLco) possibly indicating emphysema.~17. Significant exposure to environmental tobacco smoke or atmospheric or occupational pollutants~18. Urine pregnancy positive test at the Screening Visit.

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Healthy non-smokers (Type: ACTIVE_COMPARATOR): 10 healthy non-smokers will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
- Smokers without COPD (Type: EXPERIMENTAL): 10 smokers without COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.
- Ex-smokers with COPD (Type: EXPERIMENTAL): 10 ex-smokers with COPD will receive 50 mg of Losartan for 4 consecutive weeks followed by 100 mg of Losartan for 4 consecutive weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).